ZLAB Quote, Financials, Valuation and Earnings

Dr. Reddy's Laboratories Ltd. has a net margin of -39.51% compared to Zai Lab Ltd.'s net margin of 13.63%. Zai Lab Ltd.'s return on equity of -22.45% beat Dr. Reddy's Laboratories Ltd.'s return on equity of 15.8%.

Zai Lab Ltd. has a consensus price target of $39.10, signalling upside risk potential of 112.86%. On the other hand Dr. Reddy's Laboratories Ltd. has an analysts' consensus of $14.32 which suggests that it could grow by 1.37%. Given that Zai Lab Ltd. has higher upside potential than Dr. Reddy's Laboratories Ltd., analysts believe Zai Lab Ltd. is more attractive than Dr. Reddy's Laboratories Ltd..

Zai Lab Ltd. has a beta of 0.854, which suggesting that the stock is 14.611% less volatile than S&P 500. In comparison Dr. Reddy's Laboratories Ltd. has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.33%.

Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dr. Reddy's Laboratories Ltd. offers a yield of 0.66% to investors and pays a quarterly dividend of $0.09 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Dr. Reddy's Laboratories Ltd. pays out 8.91% of its earnings as a dividend. Dr. Reddy's Laboratories Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zai Lab Ltd. quarterly revenues are $128.2M, which are smaller than Dr. Reddy's Laboratories Ltd. quarterly revenues of $979.5M. Zai Lab Ltd.'s net income of -$50.6M is lower than Dr. Reddy's Laboratories Ltd.'s net income of $133.5M. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Dr. Reddy's Laboratories Ltd.'s PE ratio is 18.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.36x versus 2.97x for Dr. Reddy's Laboratories Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Sinovac Biotech Ltd. has a net margin of -39.51% compared to Zai Lab Ltd.'s net margin of --. Zai Lab Ltd.'s return on equity of -22.45% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.

Zai Lab Ltd. has a consensus price target of $39.10, signalling upside risk potential of 112.86%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Zai Lab Ltd. is more attractive than Sinovac Biotech Ltd..

Zai Lab Ltd. has a beta of 0.854, which suggesting that the stock is 14.611% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.790, suggesting its less volatile than the S&P 500 by 21.049%.

Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.

Zai Lab Ltd. quarterly revenues are $128.2M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. Zai Lab Ltd.'s net income of -$50.6M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.36x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

111, Inc. has a net margin of -39.51% compared to Zai Lab Ltd.'s net margin of -0.5%. Zai Lab Ltd.'s return on equity of -22.45% beat 111, Inc.'s return on equity of -26.11%.

Zai Lab Ltd. has a consensus price target of $39.10, signalling upside risk potential of 112.86%. On the other hand 111, Inc. has an analysts' consensus of -- which suggests that it could grow by 812.48%. Given that 111, Inc. has higher upside potential than Zai Lab Ltd., analysts believe 111, Inc. is more attractive than Zai Lab Ltd..

Zai Lab Ltd. has a beta of 0.854, which suggesting that the stock is 14.611% less volatile than S&P 500. In comparison 111, Inc. has a beta of 0.546, suggesting its less volatile than the S&P 500 by 45.375%.

Zai Lab Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 111, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab Ltd. pays -- of its earnings as a dividend. 111, Inc. pays out -- of its earnings as a dividend.

Zai Lab Ltd. quarterly revenues are $128.2M, which are smaller than 111, Inc. quarterly revenues of $419.3M. Zai Lab Ltd.'s net income of -$50.6M is lower than 111, Inc.'s net income of -$2.1M. Notably, Zai Lab Ltd.'s price-to-earnings ratio is -- while 111, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab Ltd. is 4.36x versus 0.03x for 111, Inc.. Usually stocks with elevated PS ratios are considered overvalued.